Evidence map›Paper›PMID 30166612›Full record

ArticleScientific reports2018

OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.

Paloma Del C Monroig-Bosque, Maitri Y Shah, Xiao Fu, Enrique Fuentes-Mattei, Hui Ling, Cristina Ivan, Nazila Nouraee, Beibei Huang, Lu Chen, Valentina Pileczki and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. The emerging role of miR-10 family in gastric cancer.Cell cycle (Georgetown, Tex.) · 2021
    Review
  12. Review
  13. Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  14. MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 8 countries.

Paloma Del C Monroig-BosqueDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maitri Y ShahDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiao FuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Enrique Fuentes-MatteiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-2529-8256
Hui LingDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cristina IvanCenter for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4848-0168
Nazila NouraeeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Beibei HuangIntelligent Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lu ChenIntelligent Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-0765-6662
Valentina PileczkiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roxana S RedisDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eun-Jung JungDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xinna ZhangCenter for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael LehrerDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rahul NagvekarDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ana Carolina P MafraDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria Del Mar Monroig-BosqueDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexandra IrimieDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Carlos RiveraDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Calin Dan DumitruScripps Laboratories for tRNA Synthetase Research, The Scripps Research Institute, La Jolla, California, USA.
Ioana Berindan-NeagoeThe Research Center for Functional Genomics, Biomedicine and Translational Medicine University of Medicine and Pharmacy 'I. Hatieganu', Cluj-Napoca, Romania.
Edward P NikonowiczDepartment of Biochemistry and Cell Biology, Rice University, Houston, TX, USA.
Shuxing ZhangIntelligent Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. gcalin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USIuliu Hațieganu University of Medicine and Pharmacy · RORice University · USScripps Research Institute · US

Funding

UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
NCATS NIH HHS UH3 TR000943NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA182905NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

The pervasive role of microRNAs (miRNAs) in cancer pathobiology drives the introduction of new drug development approaches such as miRNA inhibition. In order to advance miRNA-therapeutics, meticulous screening strategies addressing specific tumor targets are needed. Small molecule inhibitors represent an attractive goal for these strategies. In this study, we devised a strategy to screen for small molecule inhibitors that specifically inhibit, directly or indirectly, miR-10b (SMIRs) which is overexpressed in metastatic tumors. We found that the multi-tyrosine kinase inhibitor linifanib could significantly inhibit miR-10b and reverse its oncogenic function in breast cancer and liver cancer both in vitro and in vivo. In addition, we showed that the efficacy of linifanib to inhibit tyrosine kinases was reduced by high miR-10b levels. When the level of miR-10b is high, it can "hijack" the linifanib and reduce its kinase inhibitory effects in cancer resulting in reduced anti-tumor efficacy. In conclusion, our study describes an effective strategy to screen for small molecule inhibitors of miRNAs. We further propose that miR-10b expression levels, due to the newly described "hijacking" effect, may be used as a biomarker to select patients for linifanib treatment.

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmLiver NeoplasmsFemaleHep G2 CellsHumansIndazolesMaleMCF-7 CellsMicroRNAsNeoplasm MetastasisPhenylurea CompoundsRNA, NeoplasmIndazoleslinifanibMicroRNAsMIRN10 microRNA, humanPhenylurea CompoundsRNA, Neoplasm

Identifiers

PMID30166612
PMCPMC6117344
OpenAlexW2888027727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.